Semi-Annual Statement Of Changes In Equity

Perseus Proteomics Inc. - Filing #7332021

Concept 2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
As at
2023-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
As at
2023-03-31
As at
2023-03-31
As at
2023-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
As at
2023-03-31
As at
2022-03-31
As at
2022-03-31
As at
2022-03-31
As at
2022-03-31
As at
2022-03-31
As at
2022-03-31
As at
2022-03-31
As at
2022-03-31
As at
2022-03-31
Semi-annual statement of changes in equity
Statement of changes in equity
Net assets
1,324,205,000 JPY
2,256,908,000 JPY
2,256,908,000 JPY
-21,000 JPY
-2,903,700,000 JPY
74,139,000 JPY
1,971,019,000 JPY
1,398,344,000 JPY
-2,903,700,000 JPY
1,939,252,000 JPY
-1,799,240,000 JPY
2,396,545,000 JPY
2,225,142,000 JPY
2,225,142,000 JPY
31,411,000 JPY
-20,000 JPY
2,365,134,000 JPY
-1,799,240,000 JPY
2,225,142,000 JPY
JPY
-1,012,240,000 JPY
1,939,252,000 JPY
JPY
3,152,154,000 JPY
-1,012,240,000 JPY
2,225,142,000 JPY
3,152,154,000 JPY
Changes during period
Profit (loss)
-1,104,460,000 JPY
-1,104,460,000 JPY
-1,104,460,000 JPY
-1,104,460,000 JPY
-786,999,000 JPY
-786,999,000 JPY
-786,999,000 JPY
-786,999,000 JPY
Net changes in items other than shareholders' equity
42,727,000 JPY
42,727,000 JPY
31,411,000 JPY
31,411,000 JPY
Total changes during period
31,766,000 JPY
31,766,000 JPY
-1,104,460,000 JPY
-1,040,928,000 JPY
-998,200,000 JPY
31,766,000 JPY
-1,000 JPY
42,727,000 JPY
-1,104,460,000 JPY
31,411,000 JPY
-755,608,000 JPY
-786,999,000 JPY
-786,999,000 JPY
-787,019,000 JPY
-20,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.